CardioMetabolics Inc (CMI) - Please note our website is currently under construction.

Is a privately held, late-stage, Canadian biopharmaceutical company whose focus is commercializing drug product candidates in the novel class of energy metabolism agents. The Company has drugs in both late and early stages that target the treatment of cardiovascular disease, and related metabolic (e.g., diabetes) conditions. Cardiovascular disease is the Number 1 cause of death in North America. In particular, CMI’s technology is focused on the metabolic modulator, dichloroacetate (DCA) and related compounds which have demonstrated a special ability to positively impact the metabolism of energy. The initial target for the company’s lead candidate is to improve outcomes and recovery times for patients undergoing open heart surgical procedures (ex. Coronary artery bypass).

CMI is located in Edmonton, Alberta, with strategic proximity to centres of scientific and clinical excellence in cardiovascular research.

Please contact us: